DR-18 based CAR-T
/ Simcha Therap, J&J
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 08, 2024
Simcha Therapeutics Announces License & Option Agreement to Develop Novel Decoy-resistant IL-18 for Use in Cell Therapy Applications
(Businesswire)
- "Simcha Therapeutic...today announced that it has entered into a license and option agreement with Janssen Biotech, Inc. ('Janssen'), a Johnson & Johnson company, where Janssen will work to armor select CAR T-based cell therapy candidates with Simcha’s novel proprietary decoy-resistant IL-18 (DR-18). The agreement was facilitated by Johnson & Johnson Innovation....Under the terms of the agreement, Janssen will develop, manufacture, and commercialize DR-18 armored cell therapies for a set number of programs. In exchange, Simcha will receive an undisclosed upfront fee, potential option exercise fees and development and commercialization milestone payments."
Licensing / partnership • Oncology
1 to 1
Of
1
Go to page
1